Unitaid, a global health initiative, said a generic of Dolutegravir (DTG), first approved in the United States in 2013, is being given to 20,000 patients in Kenya before being rolled out in Nigeria and Uganda later in the year.
The brand name version of DTG is Tivicay, produced by ViiV Healthcare, which is majority-owned by GlaxoSmithKline. DTG is the drug of choice for people with HIV in high-income countries who have never taken antiretroviral therapy before, and for those who have developed resistance to other treatments. Kenya is the first African country to start using the DTG.
“I had constant nightmares and no appetite,” said Nairobi resident Doughtiest Ogutu, who started taking the drug this year because of her resistance to other treatments. “My appetite has come back… My body is working well with it.”
Ogutu, who has been living with HIV for 15 years, said her viral load, the amount of HIV in her blood, has fallen tenfold from 450,000 to 40,000 since she started on DTG.
Sub-Saharan Africa has been at the epicenter of the HIV epidemic for decades and home to nearly three quarters of all people with HIV and AIDS.
No comments:
Post a Comment
Please share your view about the article in the Comment section.